Pulaive Pharma has recently submitted its listing application to the Hong Kong Stock Exchange main board, with CITIC Securities as the sole sponsor. This marks the company's second filing, following its initial submission on February 13. Public records show that since its inception, the company has completed six funding rounds from Pre-A to D+, raising approximately RMB 787 million in total, with a post-investment valuation of RMB 2.505 billion. Participating investors include PICC Science and Technology Innovation Fund and Yifeng Runjun, among others.

According to available information, the company's core product, PL-5, is the world's first approved First-in-Class (FIC) Janus-type anti-infective drug, which received marketing approval in June 2026. However, it has yet to generate commercial revenue, and the company remains in a loss-making position. From a market perspective, the long-standing issue of antibiotic abuse persists, and as one of the world's rare polypeptide antimicrobial drugs, the commercial prospects of the company's core product remain uncertain.

Accumulated losses exceed RMB 300 million; core product has yet to turn profitable

Founded in April 2009, Pulaive Pharma is an antimicrobial peptide (AMP) therapeutic drug company focused on two core therapeutic areas: anti-infection and metabolic diseases. From a financial standpoint, for the fiscal years 2024 and 2025, and the six months ended June 30, 2026, the company recorded revenues of approximately RMB 5.194 million, RMB 3.332 million, and RMB 2.192 million respectively, with gross profits of approximately RMB 2.174 million, RMB 1.308 million, and RMB 1.050 million. During these periods, losses amounted to approximately RMB 158 million, RMB 142 million, and RMB 85.24 million respectively.

According to data from Zhitong Finance APP, all of the company's current revenue derives from daily care products, a segment that is not its core business but rather serves as a cash flow supplement during the R&D phase. Although the core innovative drug PL-5 has signed an exclusive cooperation agreement with Chia Tai Tianqing, it has yet to generate commercial revenue. While first-half 2026 revenue grew 53.5% year-over-year, the overall scale of the daily care business remains small and offers very limited support to the company's operations.

The fluctuation in losses is driven by both R&D expenditures and financing costs. The net loss in 2025 narrowed by 10.6% year-over-year, primarily because R&D expenses fell 29.1% year-over-year following the NDA submission of the core product PL-5. In the first half of 2026, the loss expanded by 28.5% year-over-year, mainly due to a significant increase in financing costs from interest on equity buyback liabilities, which eroded current cash flow.

As of June 30, 2026, the company held only RMB 34.05 million in cash and cash equivalents, while net current liabilities had climbed to RMB 974 million. Both the current ratio and quick ratio stood at just 0.11, indicating insufficient short-term solvency. In the first half of 2026, net cash outflow from operating activities was RMB 40.819 million. At the current burn rate, existing cash reserves can only cover approximately eight months of operations.

A pipeline built on antimicrobial peptides; antibiotic resistance poses a global challenge

Pulaive Pharma's R&D pipeline is built on the "membrane-disruption mechanism" theory. Through novel peptide molecular design, antimicrobial peptides can precisely destroy bacterial cell membranes without harming normal human cells. Compared with traditional antibiotics, antimicrobial peptides (AMPs) not only exhibit broad-spectrum antibacterial activity but also maintain killing efficacy against many bacterial strains that have developed resistance to conventional antibiotics. This characteristic addresses the most urgent clinical need in the anti-infection field today.

With the widespread use of antimicrobial drugs, pathogen resistance has become increasingly severe. Many pathogenic bacteria have developed multi-drug resistance to traditional antibiotics, prompting the World Health Organization to declare antimicrobial resistance one of the world's top public health threats of the 21st century. According to the WHO's 2025 Global Antimicrobial Resistance Surveillance Report, one in six laboratory-confirmed bacterial infections causing common illnesses worldwide in 2023 were resistant to antibiotic treatment. Between 2018 and 2023, more than 40% of monitored pathogen-antibiotic combinations saw increased resistance, with an average annual increase ranging from 5% to 15%.

According to data from Zhitong Finance APP, Pulaive Pharma's core product PL-5 (pelagacarb) is administered as a topical spray for treating secondary infections of first- or superficial second-degree burn wounds (burn wound secondary infections) and diabetic foot infections (DFI) caused by Staphylococcus epidermidis, Staphylococcus haemolyticus, or Acinetobacter baumannii. It is the world's first Janus-class drug to receive New Drug Application (NDA) approval as a First-in-Class therapy.

PL-5 has previously demonstrated encouraging efficacy and safety, showing activity against multiple multi-drug resistant pathogens. Clinical data indicate that PL-5 can completely eradicate drug-resistant bacteria in certain cases, including Pseudomonas aeruginosa, Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus, and NDM-1 gene-carrying multi-drug resistant Acinetobacter baumannii — pathogens that WHO data identifies as among the most clinically challenging resistant strains globally. The company has completed a Phase III clinical trial in China for PL-5 targeting secondary wound infections, receiving NDA approval in June 2026, making it a First-in-Class Janus-type anti-infective drug. Simultaneously, the company is conducting a Phase II clinical trial in the United States to expand the indication to diabetic foot infections, expected to be completed by the third quarter of 2028.

Regarding commercialization arrangements, PL-5 entered into an exclusive commercial cooperation agreement with Chia Tai Tianqing in December 2022. During the cooperation period, the company has granted Chia Tai Tianqing exclusive rights to promote PL-5 and conduct other commercialization activities in mainland China for all indications approved by relevant authorities. The company will continue to be responsible for PL-5's R&D, global clinical trials, and regulatory strategy while retaining commercialization rights outside mainland China during the cooperation period.

Beyond the core product PL-5, Pulaive Pharma has also positioned two additional anti-infective drug candidates, PL-3301 and PL-18, while extending its preclinical pipeline into therapeutic areas such as metabolic diseases. PL-3301 is a potential First-in-Class thermosensitive peptide gel for treating oropharyngeal candidiasis (OPC), a condition commonly seen in immunocompromised populations such as HIV patients, cancer patients after chemotherapy, and elderly individuals on long-term steroid use. Current treatments primarily rely on azole antifungal drugs, but resistance issues persist in this area as well. The product is currently undergoing a Phase Ia clinical trial in China, received FDA approval for a Phase I clinical trial in the U.S. in 2024, and is expected to commence Phase II in China in September 2026. Additionally, the company is advancing preclinical development of PL-3301 for pulmonary infection indications and plans to submit a new drug clinical trial application for this indication by December 2027.

Another major product, PL-18, is a potential First-in-Class AMP drug for treating vulvovaginal candidiasis (VVC) and may also be applicable to a range of gynecological infections, including bacterial vaginosis, fungal vaginitis, and mixed vaginitis. The product is currently undergoing a Phase II clinical trial in China and has received FDA approval for a Phase II clinical trial in the U.S.

In addition to the anti-infective drugs mentioned above, Pulaive Pharma is actively expanding its pipeline into therapeutic areas including metabolic diseases, oncology, and autoimmune diseases, with multiple assets currently in preclinical stages. According to data from Zhitong Finance APP, the preclinical asset PL-MD-333 is an oral FGF19/FGF21 inducer and lipid metabolism modulator. Preclinical studies indicate that PL-MD-333 can reduce fat mass, increase lean muscle percentage, and exhibit synergistic effects when combined with GLP-1 receptor agonists such as semaglutide, positioning it as a potential candidate that could transform metabolic disease treatment paradigms.

Overall, against the backdrop of increasingly severe global antibiotic resistance, antimicrobial peptides as a novel class of anti-infective drugs present broad market prospects. Pulaive Pharma's core pipeline PL-5, as China's first antimicrobial peptide innovative drug, is at the forefront of R&D progress, with its unique clinical value constituting the company's most critical competitive moat. However, it is worth noting that PL-5's approval came only recently and it has not yet entered the commercialization phase. The pace of subsequent medical insurance negotiations and hospital formulary inclusion remains uncertain, and the effectiveness of the promotional cooperation with Chia Tai Tianqing will take time to verify. Meanwhile, most of the follow-up pipeline remains in early-stage development, making it difficult for the company to achieve profitability in the near term. During this period when commercial value has yet to be realized, the market may adopt a relatively cautious stance toward the company's valuation.